Trevena Inc (TRVN):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Trevena Inc (TRVN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C7569)・商品コード:DATA904C7569
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:48
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Trevena Inc (Trevena) is a biotechnology company that discovers and develops G-protein coupled receptor targeted medicines. The company provides products such as RV027, TRV130, TRV734 and TRV250. Its TRV027 is an intravenous drug used for the treatment of acute heart failure in combination with standard diuretic therapy. Trevena’s TRV130 is an intravenous G protein biased ligand that targets the mu opioid receptor. The company’s GPCR is associated with beneficial versus adverse biological effects. Its TRV250 is an oral delta opioid biased ligand for treatment of refactory migraine. It operates in the US. Trevena is headquartered in Chesterbrook, Pennsylvania, the US.

Trevena Inc (TRVN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Trevena Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Trevena Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Trevena Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Trevena To Raise US$60 Million In Series C Financing 11
Partnerships 13
Trevena Enters Into Research Agreement With Merck For Biased Ligand Molecules 13
Licensing Agreements 14
Jiangsu Nhwa Pharma Enters into Licensing Agreement with Trevena 14
Pharmbio Korea Enters into Licensing Agreement with Trevena 15
Equity Offering 16
Trevena to Raise up to USD50 Million in Public Offering of Shares 16
Trevena Raises USD73 Million in Public Offering of Shares 17
Trevena Raises USD51.4 Million in Public Offering of Shares 19
Trevena Completes Underwriters Exercise Of Over-Allotment Of IPO For US$66.6 Million 21
Trevena Inc – Key Competitors 23
Trevena Inc – Key Employees 24
Trevena Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
Aug 02, 2018: Trevena reports second quarter 2018 financial results 26
May 03, 2018: Trevena Reports First Quarter 2018 Financial Results 28
Mar 07, 2018: Trevena Reports Full Year 2017 Earnings 29
Nov 07, 2017: Trevena Reports Third Quarter 2017 Financial Results and Announces New Positive Clinical Trial Data 31
Aug 03, 2017: Trevena Reports Second Quarter 2017 Financial Results and Provides Corporate Update 33
May 04, 2017: Trevena Reports First Quarter 2017 Financial Results and Provides Corporate Update 35
Mar 08, 2017: Trevena Reports Full Year 2016 Earnings 36
Corporate Communications 38
Oct 01, 2018: Trevena announces completion of leadership transition and appointment of new director 38
May 21, 2018: Trevena Names Mark A. Demitrack As Chief Medical Officer 39
Apr 05, 2018: Trevena Announces Retirement of Maxine Gowen and Planned Promotion of Carrie L. Bourdow to President and Chief Executive Officer 40
Feb 02, 2018: Trevena Announces Promotion Of Carrie Bourdow to Executive Vice President and Chief Operating Officer 41
Aug 14, 2017: Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 42
Clinical Trials 43
Apr 06, 2017: Trevena Announces Presentations at the 42nd Annual Regional Anesthesiology and Acute Pain Medicine Meeting 43
Feb 21, 2017: Trevena Announces Positive Top-line Results from Two Phase 3 Pivotal Efficacy Studies of Intravenous Oliceridine in Moderate-to-Severe Acute Pain 45
Jan 04, 2017: Trevena Completes Enrollment of Phase 3 APOLLO Pivotal Efficacy Trials of Oliceridine for Moderate-to-Severe Acute Pain 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Trevena Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Trevena Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Trevena Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Trevena Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Trevena To Raise US$60 Million In Series C Financing 11
Trevena Enters Into Research Agreement With Merck For Biased Ligand Molecules 13
Jiangsu Nhwa Pharma Enters into Licensing Agreement with Trevena 14
Pharmbio Korea Enters into Licensing Agreement with Trevena 15
Trevena to Raise up to USD50 Million in Public Offering of Shares 16
Trevena Raises USD73 Million in Public Offering of Shares 17
Trevena Raises USD51.4 Million in Public Offering of Shares 19
Trevena Completes Underwriters Exercise Of Over-Allotment Of IPO For US$66.6 Million 21
Trevena Inc, Key Competitors 23
Trevena Inc, Key Employees 24

List of Figures
Trevena Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Trevena Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Trevena Inc (TRVN):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C7569)販売に関する免責事項を必ずご確認ください。
★調査レポート[Trevena Inc (TRVN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆